Exploring the role of the inflammasomes on prostate cancer: Interplay with obesity

Author:

Pérez-Gómez Jesús M.ORCID,Montero-Hidalgo Antonio J.ORCID,Fuentes-Fayos Antonio C.ORCID,Sarmento-Cabral AndréORCID,Guzmán-Ruiz RocioORCID,Malagón María M.ORCID,Herrera-Martínez Aura D.ORCID,Gahete Manuel D.ORCID,Luque Raúl M.ORCID

Abstract

AbstractObesity is a weight-related disorder characterized by excessive adipose tissue growth and dysfunction which leads to the onset of a systemic chronic low-grade inflammatory state. Likewise, inflammation is considered a classic cancer hallmark affecting several steps of carcinogenesis and tumor progression. In this regard, novel molecular complexes termed inflammasomes have been identified which are able to react to a wide spectrum of insults, impacting several metabolic-related disorders, but their contribution to cancer biology remains unclear. In this context, prostate cancer (PCa) has a markedly inflammatory component, and patients frequently are elderly individuals who exhibit weight-related disorders, being obesity the most prevalent condition. Therefore, inflammation, and specifically, inflammasome complexes, could be crucial players in the interplay between PCa and metabolic disorders. In this review, we will: 1) discuss the potential role of each inflammasome component (sensor, molecular adaptor, and targets) in PCa pathophysiology, placing special emphasis on IL-1β/NF-kB pathway and ROS and hypoxia influence; 2) explore the association between inflammasomes and obesity, and how these molecular complexes could act as the cornerstone between the obesity and PCa; and, 3) compile current clinical trials regarding inflammasome targeting, providing some insights about their potential use in the clinical practice.

Funder

Ministerio de Ciencia, Innovación y Universidades

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Reference236 articles.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

2. Eeles RA, Dearnaley DP, ArdernJones A, Shearer RJ, Easton DF, Ford D, Edwards S, Dowe A, Anderson J, Archibold J, Bailey M, Barker C, Bellringer J, Bishop DT, Bishop M, Bolger J, Boyd J, Budd D, Butler M, Brookstein R, Charig C, Conn I, Cranston C, Crundwell M, Das G, Doble A, Duncan W, Duchesne J, Eccles D, Fawcett D, Fisher C, Fletcher M, Fowler JW, Gallegos C, Ghaznavi A, Gilbert H, Glaholm J, Gordon E, Hampson S, Hanbury DC, Hargreave T, Harland S, Harrison GS, Harrison NW, Hart JL, Hehir M, Hendry W, Higgins A, Hopper J, Horwich A, Hughes M, Irving S, James N, Jenkins IL, Jones C, Key T, Kaisary A, Kirby R, Kirk D, Lee J, Lemberger R, Lloyd S, Lynch M, Malone PR, Mansi J, Mason M, McEwan AB, McNicholas TA, Moffat LEF, Morgan RJ, Murday V, Muir G, Munson KW, Murray K, Murrell S, Newman H, Oboyle PJ, Odonoghue E, Notley RG, Pengelly A, Philip T, Plail R, Powell C, Russell J, Read G, Reddy PJ, Richmond W, Roberts T, Rowley K, Rouse AD, Russell RM, Ryan P, Senanayake L, Sandhu D, Shridhar P, Shweitzer R, Shearer R, Smith J, Smith P, Stockdale A, Stower M, Thomas P, Terry T, Thurston A, Tullock D, Turner G, Wallace M, Weston P, Whelan P, Whillis D, Wilson R, Williams G, Woodhouse C. Familial prostate cancer: The evidence and the Cancer Research Campaign British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study. Br J Urol. 1997;79:8–14. https://doi.org/10.1111/j.1464-410X.1997.tb00795.x.

3. De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schroder F, Sciarra A, Tubaro A. The controversial relationship between benign prostatic hyperplasia and prostate cancer: The role of inflammation. Eur Urol. 2011;60(1):106–17. https://doi.org/10.1016/j.eururo.2011.03.055.

4. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: Weighing the evidence. Eur Urol. 2013;63(5):800–9. https://doi.org/10.1016/j.eururo.2012.11.013.

5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3